David C. Danko, PhD, is the Chief Technology Officer of Biotia, where he leads the software engineering team and designs end-to-end computational pipelines for extracting microbial diagnostic insights from next-generation sequencing data. He oversees the technical architecture behind Biotia's clinical metagenomic assays, BIOTIA-DX, BIOTIA-ID, and the GeoSeeq global outbreak surveillance platform.

David C. Danko earned his PhD in computational biology from Weill Cornell Medicine, where he studied the impact of environmental microbiomes on human health, and his undergraduate degree in computer science from the Massachusetts Institute of Technology. During his graduate work he also studied at the Oxford Kennedy Institute of Rheumatology. His research has focused on understanding immune responses to environmental microbes and characterizing how microbiomes change during human spaceflight.

He is a contributor to MetaSUB, an international consortium that has identified thousands of previously unknown bacterial and viral species from urban transit systems and hospitals across more than 60 cities in 32 countries. His work bridges machine learning, software engineering, and microbial genomics, and continues to inform Biotia's approach to scalable, AI-driven infectious disease diagnostics.